This morning Moberg Pharma confirms that the coronavirus outbreak has not had any impact on the Phase 3 European MOB-015 study. The last patient has had its final study-related visit, and Moberg reiterates that topline results are expected late in Q2 2020. We believe the current valuation is attractive out of a risk-reward perspective.